Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 267

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 267
---
 2023

        2022

        Accounts receivable, net, current and non-current:

        Beginning of period
         
        $
        25,491

        $
        29,586

        $
        34,701

        End of period
         
        $
        20,947

        $
        25,491

        $
        29,586

        Contract assets:

        Beginning of period
         
        $
        —

        $
        —

        $
        1,074

        End of period
         
        $
        239

        $
        —

        $
        —

        Deferred revenue:

        Beginning of period
         
        $
        148

        $
        1,829

        $
        3,333

        End of period
         
        $
        115

        $
        148

        $
        1,829

        Revenue recognized during the period from:

        Amounts included in deferred revenue at beginning of period
         
        $
        148

        $
        1,708

        $
        3,333

        Performance obligations satisfied in previous periods
         
        $
        81,585

        $
        87,152

        $
        101,921

       As of December 31, 2024, the Company had recorded deferred revenue of $0.1 million which represents consideration received or unconditionally due from licensees for performance obligations that have not yet been satisfied by the Company. Unsatisfied performance obligations as of December 31, 2024 consisted of development services to be performed by the Company related to licensed products, which will be satisfied as the services are performed. As of December 31, 2024, the aggregate transaction price of the Company's license agreements allocated to performance obligations not yet satisfied, or partially satisfied, was $1.1 million, which is expected to be satisfied over a period of approximately two years.Revenue recognized from performance obligations satisfied in previous periods, as presented in the table above, was primarily attributable to Zolgensma royalties and changes in the transaction prices of the Company’s license agreements. Changes in transaction prices were primarily attributable to development milestones achieved or deemed probable of achievement during the periods which were previously not considered probable of achievement, resulting in a cumulative catch-up adjustment to revenue. Revenue recognized during the years ended December 31, 2024, 2023 and 2022 included zero, $2.